Lisata Therapeutics Inc (LSTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.90+2.15%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Improve net income and operating income: metric not reported.
Lisata is completing its acquisition by Kuva Labs, which could unlock value. The company aims to improve financial performance after reporting a net loss of $4.49M and operating loss of $4.94M in 2026-Q1. The market implies 23.7% growth over 3 years, reflecting optionality in the turnaround.
Lisata remains loss-making with negative EPS of -$1.09 in 2026 and -$1.16 in 2027. Financial improvement progress is weak with a management progress score of 32%. The recent 34.7% share price drop signals market doubts about the turnaround.
The market prices Lisata near our fair value of $1.72 with implied 3-year growth of 23.7%. Our view aligns with this optionality but remains cautious given ongoing losses and weak financial progress.
Breaks if: Acquisition not completed by end of 2026
Breaks if: EPS loss worsens or remains flat through FY27
Breaks if: Net loss and operating loss do not improve by 50% by FY27
Focus on improving financial results through cost management and operational efficiency.
Stated as a priority in 5 of last 5 quarters. Net income improved from -$4.66M in 2025-Q2 to -$2.93M in 2026-Q2, showing some progress in reducing losses. Operating income also improved from -$4.87M to -$3.99M over the same period. Management's focus on financial performance is persistent and the trajectory shows limited but positive progress.
“Focus on improving financial performance and managing costs.”
“Continued efforts to improve financial results and reduce losses.”
“Emphasis on cost control and financial performance improvement.”
“Ongoing initiatives to improve financial metrics and reduce expenses.”
“Management committed to improving financial performance.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation, as LSTA is currently loss-making and experiencing volatility in management and performance. The company is focused on completing an acquisition and reducing operating expenses, but it has not yet shown financial improvement.
The current valuation suggests that the market has priced in a low level of fragility, with a premium compared to peers. Recent changes indicate a rise in valuation and composite insight, but expectations remain cautious.
Fundamentals are likely to remain under pressure in the near term due to ongoing losses and operational challenges. The company's efforts to reduce expenses and explore strategic alternatives are still in early stages, with no immediate financial impact evident.
The thesis hinges on several factors, including the completion of the acquisition by Kuva Labs and the ability to reduce operating expenses effectively. Additionally, the performance of sector bellwethers and broader economic indicators, such as job growth, will influence LSTA's trajectory.
In the next 1 to 3 years, LSTA's performance will depend on its operational execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.